http://www.nejm.org/doi/full/10.1056/NEJMoa1607427 Strosberg J 1 , El-Haddad G 1 , Wolin E 1 , Hendifar A 1 , Yao J 1 , Chasen B 1 , Mittra E 1 , Kunz PL 1 , Kulke MH 1 , Jacene H 1 , Bushnell D 1 , O'Dorisio TM 1 , Baum RP 1 , Kulkarni HR 1 , Caplin M 1 , Lebtahi R 1 , Hobday T 1 , Delpassand E 1 , Van Cutsem E 1 , Benson A 1 , Srirajaskanthan R 1 , Pavel M 1 , Mora J 1 , Berlin J 1 , Grande E 1 , Reed N 1 , Seregni E 1 , Öberg K 1 , Lopera Sierra M 1 , Santoro P 1 , Thevenet T 1 , Erion JL 1 , Ruszniewski P 1 , Kwekkeboom D 1 , Krenning E 1 ; NETTER-1 Trial Investigators . Author information Abstract Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin an...